Progressive multiple sclerosis, cognitive function, and quality of life

Chow, Helene Højsgaard; Schreiber, Karen; Magyari, Melinda; Ammitzbøll, Cecilie; Börnsen, Lars; Christensen, Jeppe Romme; Ratzer, Rikke; Sørensen, Per Soelberg; Sellebjerg, Finn

doi:10.1002/brb3.875

Cited by 58 publications

(38 citation statements)

References 53 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple sclerosis (MS) is a chronic autoimmune inflammatory disorder affecting the central nervous system (CNS) [ 98 , 99 ]. Multiple sclerosis is the most common inflammatory neurological disease in young adults [ 100 ].…”

Section: Discussionmentioning

confidence: 99%

The Treatment of Cognitive, Behavioural and Motor Impairments from Brain Injury and Neurodegenerative Diseases through Cannabinoid System Modulation—Evidence from In Vivo Studies

Calina

Buga

Mitroi

et al. 2020

JCM

View full text Add to dashboard Cite

Neurological disorders such as neurodegenerative diseases or traumatic brain injury are associated with cognitive, motor and behavioural changes that influence the quality of life of the patients. Although different therapeutic strategies have been developed and tried until now to decrease the neurological decline, no treatment has been found to cure these pathologies. In the last decades, the implication of the endocannabinoid system in the neurological function has been extensively studied, and the cannabinoids have been tried as a new promising potential treatment. In this study, we aimed to overview the recent available literature regarding in vivo potential of natural and synthetic cannabinoids with underlying mechanisms of action for protecting against cognitive decline and motor impairments. The results of studies on animal models showed that cannabinoids in traumatic brain injury increase neurobehavioral function, working memory performance, and decrease the neurological deficit and ameliorate motor deficit through down-regulation of pro-inflammatory markers, oedema formation and blood–brain barrier permeability, preventing neuronal cell loss and up-regulating the levels of adherence junction proteins. In neurodegenerative diseases, the cannabinoids showed beneficial effects in decreasing the motor disability and disease progression by a complex mechanism targeting more signalling pathways further than classical receptors of the endocannabinoid system. In light of these results, the use of cannabinoids could be beneficial in traumatic brain injuries and multiple sclerosis treatment, especially in those patients who display resistance to conventional treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

The Treatment of Cognitive, Behavioural and Motor Impairments from Brain Injury and Neurodegenerative Diseases through Cannabinoid System Modulation—Evidence from In Vivo Studies

Calina

Buga

Mitroi

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Cognitive impairment appears to be associated with increased rates of unemployment and lower measures of QOL (107). The most common scales to measure quality of life in cognitive studies are EuroQOL five dimension questionnaire, a generic health-related QOL scale and the Short Form 36 (SF-36) questionnaire (107, 108).…”

Section: Impact Of Cognition In Quality Of Lifementioning

confidence: 99%

Cognitive Dysfunctions and Assessments in Multiple Sclerosis

et al. 2019

View full text Add to dashboard Cite

Cognitive impairment has been reported at all phases and all subtypes of multiple sclerosis. It remains a major cause of neurological disability in young and middle-aged adults suffering from the disease. The severity and type of cognitive impairment varies considerably among individuals and can be observed both in early and in later stages. The areas which have commonly shown more deficits are: information processing speed, complex attention, memory, and executive function. Even though an alteration in both the white matter and in the gray matter has been found in patients with multiple sclerosis and cognitive impairment, the underlying process still remains unknown. Standardized neurological examinations fail to detect emerging cognitive deficits and self-reported cognitive complaints by the patients can be confounded by other subjective symptoms. This review is a comprehensive and short update of the literature on cognitive dysfunctions, the possible confounders and the impact of quality of life in patients with multiple sclerosis.

show abstract

“…Cognitive problems affect up to 70% of people with MS (pwMS) [1] and can negatively impact quality of life and vocational activities [2] , [3] , [4] . Consequently, routine screening and management for cognitive problems in MS has been internationally recommended [ 5 , 6 ], with addressing cognitive problems a ‘top 10’ research priority for pwMS [7] .…”

Section: Introductionmentioning

confidence: 99%